؉ into the substantia nigra causes extensive necrosis and anterograde degeneration of pars compacta dopaminergic neurons. We studied secondary effects in the ipsilateral striatum by examining dopaminergic terminals, signs of neuronal damage, and glial reactivity at 1, 2, 3, and 7 days after injection of MPP ؉ into the substantia nigra. Dopaminergic terminals and uptake sites were evaluated with [
INTRODUCTION
Parkinson's disease is a common neurodegenerative disorder characterized mainly by tremor, muscular rigidity, slowness of movement, rigidity, and postural instability. This syndrome involves progressive degeneration of substantia nigra pars compacta neurons resulting in destruction of dopaminergic nigrostriatal pathways. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a remarkably selective neurotoxin, causes parkinsonism in humans (Langston et al., 1983) and when administered to monkeys and mice it reproduces many of the biochemical and neuropathological changes in the nigrostriatal dopaminergic pathway found in human Parkinson's disease (Langston & Irwin, 1986; Kopin & Markey, 1988; Heikkila et al., 1989) .
MPTP crosses the blood-brain barrier after systemic injection. Once in the brain, MPTP is bioactivated by monoamino oxidase B, which is localized in astrocytes, to its active metabolite, 1-methyl-4-phenylpyridinium (MPP ϩ ) (Chiba et al., 1984; Markey et al., 1984) . Dopaminergic neurons accumulate MPP ϩ , which enters the cells via the dopamine uptake system. MPP ϩ is concentrated inside the mitochondria, where it blocks
